Relationship between aspirin resistance and platelet membrane glycoprotein CD62p as well as GPIIb/IIIa in patients with coronary heart disease

Objective:To investigate the changes of platelet membrane glycoprotein CD62p and GPⅡb/Ⅲa in aspirin-treated patients with coronary heart disease(CHD),and to explore the relationship between CD62p or GPⅡb/Ⅲa and aspirin resistance(AR) in CHD patients.Method:CD62p-positive or GPⅡb/Ⅲa-positive platelets were detected by flow cytometry(FCM) in 60 patients with CHD(CHD group) and in 20 normal controls(NC group) before treatment.CHD patients took aspirin 100mg/d for two weeks.After treatment,CD62p-positive or GPⅡb/Ⅲa-positive platelets in patients were detected by FCM again.Platelet aggregation(PAG) induced with adenosine diphosphate(ADP) and arachidonic acid(AA) were detected.According to PAG,CHD group was divided into two subgroups:aspirin-resistant subgroup and aspirin-sensitive subgroup.Result:The numbers of CD62p-positive or GPⅡb/Ⅲa-positive platelets in patients with CHD were significantly declined after aspirin treatment(P0.01),but still higher than those of normal controls(P0.01).Aspirin-resistant were found in 8(13.3%) patients and 52(86.7%) patients were aspirin-sensitive.The numbers of GPⅡb/Ⅲa-positive platelets in aspirin-resistant subgroup were higher than those in aspirin-sensitive subgroup(P0.01).Conclusion:GPⅡb/Ⅲa may be used as one of platelet activation markers to evaluate AR in CHD patients treated with aspirin.